What is the FDA’s position on SweetLeaf Stevia™?
In August 2009, SweetLeaf™ received a “no questions” letter from the U.S. Food and Drug Administration (FDA) in regard to the findings of the FDA expert panel of scientists, which concluded that the whole leaf steviol glycosides with rebaudioside A and stevioside, used to formulate the company’s SweetLeaf Sweetener® extract, are granted Generally Recognized As Safe (GRAS) status.
Related Questions
- What is FDAs position concerning the tombstone (black and white text) provision in the 1996 rule in light of the Commonwealth decision?
- What Position Did Arthritis Foundation and American College of Rheumatology Take Following FDA Action on NSAIDs?
- What is the FDA position on unknown risks in the risk/benefit analysis?
